5.54 -0.09 (-1.60%)
After hours: 7:59PM EST
|Bid||5.54 x 21500|
|Ask||5.56 x 2900|
|Day's Range||5.61 - 6.17|
|52 Week Range||1.97 - 12.49|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2020 - May 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.89|
Endo (ENDP) delivered earnings and revenue surprises of 29.82% and 5.25%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth quarter and full year ended December 31, 2019.
NEW YORK, NY / ACCESSWIRE / February 26, 2020 / Endo International plc (NASDAQ:ENDP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 26, 2020 ...
Endo International has found its new president and chief executive officer in-house. The Dublin, Ireland-based pharmaceutical company, which has its U.S. headquarters in Malvern, said Blaise Coleman will take over as CEO effective March 6. Coleman has served as executive vice president and chief financial officer at Endo (NASDAQ: ENDP) since 2016.
DUBLIN , Feb. 19, 2020 /CNW/ -- Endo International plc (ENDP) today announced that Blaise Coleman , who has served as the Company's Executive Vice President and Chief Financial Officer since 2016, will succeed Paul Campanelli as President and Chief Executive Officer and will become a member of the Board of Directors effective March 6, 2020 . Mr. Campanelli will continue to serve as Chairman of the Board. This appointment will complete the Chief Executive Officer succession plan that Endo announced in November 2019 .
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The small-cap healthcare companies are benefiting from the 2020 presidential election campaign, which has put pressure on the large cap cousins on how to overhaul the industry.
Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States
Endo International plc (NASDAQ: ENDP) will announce its fourth-quarter and full-year 2019 financial results on February 26, 2020 and members of its senior management team will host a conference call and webcast at 8:00am EST before the U.S. financial markets open.
A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.
Two Endo International Inc. subsidiaries have agreed to pay Oklahoma $8.75 million to resolve the state’s investigation into whether the pharmaceutical company had a role in the state’s opioid abuse crisis. The settlement agreement, under which the Endo business units admitted to no wrongdoing or liability, involved Endo Pharmaceuticals Inc. and Par Pharmaceuticals. Endo officials noted the amount it agreed to pay in connection with the settlement agreement is a "fraction" of the settlement and judgment amounts associated with other opioid manufacturers in Oklahoma.
Shares of Endo International Inc. are up 3% in afternoon trading on Friday after the company said it will pay $8.75 million to Oklahoma to settle allegations that it inappropriately promoted its opioids. As part of the settlement, the company did not admit wrongdoing. According to a news release from the Attorney General's office, Endo will not employ or contract with sales reps in Oklahoma and will not pay for direct or indirect promotion of opioids. Endo has also settled similar opioid-related lawsuits with two counties in Ohio. Endo's stock has tumbled 52% over the last year. The Health Care Select Sector SPDR exchange-traded fund is up 17%.
Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. (collectively, the "Settling Parties") have executed a Settlement Agreement with the State of Oklahoma ("Oklahoma"). The Settlement Agreement fully and finally resolves Oklahoma's investigation of the Settling Parties in connection with the opioid abuse crisis in Oklahoma and includes a release of all associated claims by Oklahoma to the Settling Parties and all of their affiliated entities and persons (collectively, the "Endo Affiliates"). In connection with the Settlement Agreement, Endo Pharmaceuticals Inc. has agreed to pay $8.75 million to Oklahoma. The Settlement Agreement includes no admission of wrongdoing, fault or liability of any kind by the Endo Affiliates. The amount paid in connection with the Settlement Agreement is a fraction of the settlement and judgment amounts associated with other opioid manufacturers in Oklahoma to date and is the result of direct engagement among Oklahoma Attorney General Mike Hunter, his staff and counsel, and the Company's senior leadership.